Company Overview

Bioparin is a biotechnology company developing a synthetic variant of heparin to ensure a stable and safe supply of the critical anticoagulant drug.

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Proprietary index based on bid/ask volume and sentiment.

Track how buyer interest and sentiment changes over time.

Public and private peers based on sector, stage, and business model.

Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

Access detailed peer comparisons, multiples, and valuation benchmarks.

Historical fundraising activity

Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Feb 3, 2025
Grant	Feb 3, 2025

Notable investors and investment history

Investor	Rounds
Nucleus Grow Grant Program	Grant
National Heart, Lung, and Blood Institute	Grant

Structured signals derived from secondary market and firmographic data.

SEC and related filings with document metadata.

Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

SEC and related filings with document metadata.

Common questions about Bioparin's valuation, stock price, and market status.

HeadquartersSalt Lake City, Utah

Year FoundedN/A

Last FundingFeb 3, 2025

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.